Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.8695
−$0.0405 · -4.45%
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
Regular session
$0.8695
−$0.0405 · -4.45%
Regular session · ET · Market data may be delayed.
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
Day range
Current $0.8695
52-week range
Current $0.8695
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
26
Expensive
Sentiment
66
Bullish
Risk
77
High Risk
Momentum
56
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
Day range
Current $0.8695
52-week range
Current $0.8695
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | — | 174.84K USD | — | — |
| Gross profit | — | — | −174.84K USD | — | — |
| Research and development | 11.51M USD | 16.13M USD | 11.89M USD | 8.6B USD | 7.57M USD |
| Selling, general, and administrative | 6.46M USD | 6.09M USD | 5.98M USD | 5.83B USD | 5.02M USD |
| Operating expenses | 17.98M USD | 22.22M USD | 17.7M USD | 14.43B USD | 12.59M USD |
| Interest income | 437.93K USD | 742.36K USD | 765.39K USD | 204.36M USD | 67.93K USD |
| Depreciation and amortization | 17.28K USD | 17.28K USD | 14.62K USD | 10.08K USD | 6.76K USD |
| Operating income | −17.98M USD | −22.22M USD | −17.88M USD | −14.43B USD | −12.59M USD |
| Net income | −17.12M USD | −20.78M USD | −15.96M USD | −14.26B USD | −12.36M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 3 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI686.92K0.00%2.3T USD0.03%$378.7-0.61%
Vanguard Extended Market ETFVXF166.26K0.00%95.4B USD0.05%$232.21-0.55%
Horizon Kinetics Medical ETFMEDX20.7K0.13%16.48M USD0.85%$34.25-2.11%
Dimensional - US Sustainability Core 1 ETFDFSU1.75K0.00%2.38B USD0.15%$47.74-0.38%
Dimensional - US Core Equity 2 ETFDFAC613.230.00%88.28B USD0.21%$45.015-0.37%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFHorizon Kinetics Medical ETFMEDXDimensional - US Sustainability Core 1 ETFDFSUDimensional - US Core Equity 2 ETFDFACAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
